Antipsychotics & Diabetes: Pfizer Highlighting Differences Between Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer will launch its "Metabolics Matter" campaign in June to educate psychiatrists about the risk of diabetes associated with atypical antipsychotic agents.
You may also be interested in...
Lilly Highlights Symbyax Onset Of Action; Other Bipolar Presentations At APA
Lilly is highlighting a rapid onset of action and lack of treatment-emergent mania for its olanzapine/fluoxetine combination Symbyax, currently pending at FDA for the treatment of bipolar depression.
Lilly Highlights Symbyax Onset Of Action; Other Bipolar Presentations At APA
Lilly is highlighting a rapid onset of action and lack of treatment-emergent mania for its olanzapine/fluoxetine combination Symbyax, currently pending at FDA for the treatment of bipolar depression.
Abilify Comparative Safety Claims Require Least Favorable Dose Comparison
Comparative safety claims for Bristol-Myers Squibb/Otsuka’s atypical antipsychotic Abilify would require studies comparing the highest dose of aripiprazole to the lowest dose of the comparator or a more complicated multi-dose comparative trial, FDA review documents show.